Research Reports Initiation on Medical Supplies Stocks -- TransEnterix, Skyline Medical, Tandem Diabetes Care, and Merit Medical Systems

Thursday, May 18, 2017 Diabetes News
Email Print This Page Comment bookmark
Font : A-A+

NEW YORK, May 18, 2017 /PRNewswire/ --

On Wednesday, May 17, 2017, US markets saw broad

based losses with eight out of nine sectors finishing the trading sessions in red. Major US indices were also bearish at the close of yesterday's session. The NASDAQ Composite ended the day at 6,011.24, down 2.57%; the Dow Jones Industrial Average edged
1.78% lower, to finish at 20,606.93; and the S&P 500 closed at 2,357.03, down 1.82%. This Thursday morning, looks at the performance of these four Medical Instruments & Supplies stocks: TransEnterix Inc. (NYSE MKT: TRXC), Skyline Medical Inc. (NASDAQ: SKLN), Tandem Diabetes Care Inc. (NASDAQ: TNDM), and Merit Medical Systems Inc. (NASDAQ: MMSI). You can access our complimentary research reports on these stocks now at:


Morrisville, North Carolina headquartered TransEnterix Inc.'s stock finished Wednesday's session 2.27% higher at $0.54. A total volume of 1.21 million shares was traded, which was above their three months average volume of 1.01 million shares. The Company's shares are trading below their 50-day moving average by 46.15%. Furthermore, shares of TransEnterix, which focuses on the development and commercialization of surgical robotic systems, have a Relative Strength Index (RSI) of 23.83. Visit us today and download your complete report on TRXC for free at:

Skyline Medical  

Shares in Eagan, Minnesota-based Skyline Medical Inc. ended at $1.82, up 1.11% from the last trading session. The stock recorded a trading volume of 163,744 shares. The Company's are trading 14.59% below their 50-day moving average. Moreover, shares of Skyline Medical, which manufactures environmentally conscientious system for the collection and disposal of infectious fluids that result from surgical procedures and post-operative care in the US, have an RSI of 35.85. The complimentary research report on SKLN can be accessed at:

Tandem Diabetes Care  

San Diego, California headquartered Tandem Diabetes Care Inc.'s stock ended yesterday's session 1.06% lower at $0.90 with a total trading volume of 175,089 shares. The Company's shares are trading 29.54% below their 50-day moving average. Shares of the Company, which designs, develops, and commercializes various products for people with insulin-dependent diabetes in the US, have an RSI of 33.65. Register for free on and download the PDF research report on TNDM at:

Merit Medical Systems  

On Wednesday, shares in South Jordan, Utah headquartered Merit Medical Systems Inc. recorded a trading volume of 462,736 shares, which was above their three months average volume of 454,160 shares. The stock finished 3.50% lower at $33.10. The Company's shares have advanced 15.94% in the last one month, 17.58% in the previous three months, and 24.91% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 8.31% and 25.56%, respectively. Furthermore, shares of Merit Medical Systems, which designs, develops, manufactures, and markets medical products for interventional and diagnostic procedures worldwide, have an RSI of 54.57. Get free access to your research report on MMSI at:


Stock Callers: 

Stock Callers (SC) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. SC has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below. 

SC has not been compensated; directly or indirectly; for producing or publishing this document. 


The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by SC. SC is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.  


SC, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. SC, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, SC, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice. 


This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither SC nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit

CONTACT  For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email:  Phone number: +44-330-808-3765 Office Address: Clyde Offices, Second Floor, 48 West George Street, Glasgow, U.K. -G2 1BP

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE Chelmsford Park SA


Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions

News A - Z


News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Find a Doctor

Press Release Category

Press Release Archive

Stay Connected

  • Available on the Android Market
  • Available on the App Store